Skip to content
OpenCapital
Get started

BioSig Technologies, Inc. STEX Class of Warrant or Right, Outstanding

Other financials

Income statement

See full
Revenue$13.0K+8.3%
Gross profit$12.0K-88.9%
Operating income-$35.7M-1,098%
Net income-$46.7M-1,560%
EPS (diluted)-$0.27-92.9%

Balance sheet

See full
Cash & equivalents$6.9M+84.0%
Total debt$15.0K-94.7%
Total equity$159.0M+6,003%
Total assets$173.3M+3,823%

Cash flow

See full
Operating cash flow-$10.2M-813%
CapEx$4.0K-93.1%
Free cash flow-$2.9M+29.4%

Valuation

See full
Market cap$88.66M-61.8%
P/S2,216.6×-5,967×

Profitability

See full
Gross margin80.1%+25.2pp
Operating margin-32,155%-14,261pp
Net margin-25,825%-11,789pp
FCF margin-97,216.7%-106,293pp

Returns & leverage

See full
Return on equity-627.1%—
Debt / equity0×—
Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ClassOfWarrantOrRightOutstanding.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s class of warrant or right, outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioSig Technologies, Inc.'s class of warrant or right, outstanding?
BioSig Technologies, Inc. (STEX) reported class of warrant or right, outstanding of $1.65M in Q1 2026.
How has BioSig Technologies, Inc.'s class of warrant or right, outstanding changed year-over-year?
BioSig Technologies, Inc.'s class of warrant or right, outstanding decreased by 70.5% year-over-year, from $5.58M to $1.65M.
What is the long-term trend for BioSig Technologies, Inc.'s class of warrant or right, outstanding?
Over 5 years (2020 to 2025), BioSig Technologies, Inc.'s class of warrant or right, outstanding has grown at a 3.7% compound annual growth rate (CAGR), from $1.45M to $1.74M.